Dicot is developing the drug candidate LIB-01, which is expected to be a potency drug to treat erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are main desired properties. Dicot's main strategy is to develop LIB-01 in-house up to and including clinical phase 2a study, and then in partnership with major pharmaceutical companies to finance and further develop LIB-01 into a registered drug for the world market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 10,27 | 10,27 | 2024-03-26 |
| Bertil Lindkvist | 8,26 | 8,26 | 2023-12-27 |
| Tore Robertsson | 3,42 | 3,42 | 2024-03-26 |
| Nordnet Pensionsförsäkring | 3,20 | 3,20 | 2024-03-26 |
| Torsten Söderberg med familj | 1,98 | 1,98 | 2024-03-26 |
| Kenneth Sjökvist | 1,21 | 1,21 | 2024-03-26 |
| Klas Göran Viktor Strömberg | 1,10 | 1,10 | 2024-03-26 |
| Michael Zell | 1,00 | 1,00 | 2024-03-26 |
| Swedbank Försäkring | 0,77 | 0,77 | 2024-03-26 |
| Kenth Öhlin | 0,73 | 0,73 | 2024-03-26 |
2024-05-06 Årsstämma 2023
2024-05-06 Delårsrapport 2024-Q1
2024-08-23 Delårsrapport 2024-Q2
2024-10-31 Delårsrapport 2024-Q3
